iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
1.545
-0.015 (-0.96%)
At close: Nov 20, 2024, 4:00 PM
1.580
+0.035 (2.27%)
After-hours: Nov 20, 2024, 6:49 PM EST

Company Description

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States.

It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.

The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

iCAD, Inc.
iCAD, Inc. logo
Country United States
Founded 1984
IPO Date Dec 3, 1986
Industry Medical Devices
Sector Healthcare
Employees 69
CEO Dana Brown

Contact Details

Address:
98 Spit Brook Road, Suite 100
Nashua, New Hampshire 03062
United States
Phone 603 882 5200
Website icadmed.com

Stock Details

Ticker Symbol ICAD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000749660
CUSIP Number 44934S206
ISIN Number US44934S2068
Employer ID 02-0377419
SIC Code 3841

Key Executives

Name Position
Dana R. Brown President, Chief Executive Officer and Executive Chair
Eric Lonnqvist Chief Financial Officer
Jonathan Go Chief Technology Officer
Michelle Strong Chief Operations Officer
Annette L. Heroux Vice President of Administration
Brian Testa Chief People Officer
Bill Keyes Senior Vice President of Global Sales Operations
Vasu Avadhanula Chief Product Officer
Peter Graham Senior Vice President of North American Sales

Latest SEC Filings

Date Type Title
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Aug 14, 2024 10-Q/A [Amend] Quarterly report
Aug 14, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 2, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 14, 2024 8-K Current Report
May 15, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
Apr 29, 2024 DEF 14A Other definitive proxy statements